GlassScriptPhysician profile
Matthew W Murray
NPI 1124389366
$2,386.24
in general payments reported to CMS, 2019-2025
28 companies · $783 in 2025
The $783 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $14.18 · 2021: $74.37 · 2022: $110 · 2023: $252 · 2024: $673 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,708.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $348.55 | 2021-2025 | Freestyle Libre |
| Lilly USA, LLC | $178.53 | 2019-2025 | Zepbound, Mounjaro, Kisunla |
| Astrazeneca Pharmaceuticals LP | $176.44 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $169.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $167.28 | 2023-2025 | |
| Glaxosmithkline, LLC. | $158.20 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $138.57 | 2019-2025 | |
| Renalytix Ai, INC. | $126.24 | 2023-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Exact Sciences Corporation | $115.49 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $88.01 | 2025 | |
| Grt US Holding, INC. | $87.16 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.87 | 2019-2022 | |
| Amgen INC. | $67.19 | 2019-2025 | Evenity, Prolia, Prolia |
| Allergan, INC. | $64.87 | 2019 | |
| Lundbeck LLC | $64.61 | 2025 | Rexulti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $64.23 | 2019-2023 | Veozah |
| Sanofi-Aventis U.S. LLC | $40.66 | 2019 | |
| Corcept Therapeutics | $39.49 | 2025 | Korlym |
| Amarin Pharma, INC. | $34.11 | 2019 | |
| Hologic Sales and Service, LLC | $26.74 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $26.51 | 2025 | Gvoke Hypopen |
| Dexcom, INC. | $26.00 | 2024 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $23.68 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.82 | 2024 | Camzyos |
| Optinose US, INC. | $19.42 | 2024 | |
| Sumitomo Pharma America, INC. | $16.48 | 2023 | Gemtesa |
| Janssen Pharmaceuticals, INC | $14.86 | 2019 | |
| Melinta Therapeutics, LLC | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.